Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|March 2, 2026

BioPharm International Sponsored eBooks

  • BioPharm International Sponsored eBooks-2-26-26

Smarter Decisions, Stronger Medicines: The Role of Advanced Analytics

Pharmaceutical and biopharmaceutical companies are navigating tightening regulations, rising R&D costs, and intensifying competition, prompting a comprehensive reassessment of their production systems. By leveraging advanced analytics and modern technologies across the product lifecycle—from discovery through approval—organizations can enhance efficiency, strengthen quality and consistency, and enable more agile, data-driven manufacturing. This eBook examines how advanced analytical tools complement traditional methods to support faster, more confident decision-making within increasingly complex development and manufacturing environments.


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.